Song Lei, Chenyu Yu, Li Li, Mei Liu, Mou Yang, Hongde Hu
{"title":"Development and Validation of a Mortality Prediction Model for Left Ventricular Thrombus.","authors":"Song Lei, Chenyu Yu, Li Li, Mei Liu, Mou Yang, Hongde Hu","doi":"10.1111/pace.70014","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Left ventricular thrombus (LVT) is a severe complication associated with increased risks of systemic embolism and mortality. Despite advancements in anticoagulant therapy, optimal management strategies and risk factors for all-cause mortality remain unclear. This study aims to develop a predictive model to assess mortality risk in LVT patients and guide clinical decision-making.</p><p><strong>Methods and results: </strong>This retrospective cohort study included LVT patients diagnosed at West China Hospital (June 2018-June 2023). Patients were classified into survival and mortality groups based on all-cause mortality during follow-up. A total of 459 patients were included, randomly divided into training (n = 322) and validation (n = 137) sets. Logistic regression analysis identified seven independent predictors of mortality, which were used to construct a nomogram-based risk prediction model. The model demonstrated good discrimination with an area under the receiver operating characteristic curve (AUC) of 0.846 in the training set and 0.791 in the validation set. Key mortality predictors included elevated B-type natriuretic peptide (BNP) (OR 3.359, 95% CI 1.827-6.176, p = 0.0001), lower albumin levels (OR 0.930, 95% CI 0.882-0.981, p = 0.0077), absence of antithrombotic therapy (OR 0.468, 95% CI 0.303-0.723, p = 0.0006), and presence of malignant tumors (OR 6.199, 95% CI 1.593-24.129, p = 0.0085).</p><p><strong>Conclusion: </strong>A novel mortality prediction model for LVT patients was developed, offering a valuable tool for risk assessment and treatment optimization. This model provides a valuable tool for risk assessment and treatment optimization in Asian populations, particularly in China. Further validation is required to confirm its clinical utility.</p>","PeriodicalId":520740,"journal":{"name":"Pacing and clinical electrophysiology : PACE","volume":" ","pages":"1024-1036"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439235/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pacing and clinical electrophysiology : PACE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/pace.70014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Left ventricular thrombus (LVT) is a severe complication associated with increased risks of systemic embolism and mortality. Despite advancements in anticoagulant therapy, optimal management strategies and risk factors for all-cause mortality remain unclear. This study aims to develop a predictive model to assess mortality risk in LVT patients and guide clinical decision-making.
Methods and results: This retrospective cohort study included LVT patients diagnosed at West China Hospital (June 2018-June 2023). Patients were classified into survival and mortality groups based on all-cause mortality during follow-up. A total of 459 patients were included, randomly divided into training (n = 322) and validation (n = 137) sets. Logistic regression analysis identified seven independent predictors of mortality, which were used to construct a nomogram-based risk prediction model. The model demonstrated good discrimination with an area under the receiver operating characteristic curve (AUC) of 0.846 in the training set and 0.791 in the validation set. Key mortality predictors included elevated B-type natriuretic peptide (BNP) (OR 3.359, 95% CI 1.827-6.176, p = 0.0001), lower albumin levels (OR 0.930, 95% CI 0.882-0.981, p = 0.0077), absence of antithrombotic therapy (OR 0.468, 95% CI 0.303-0.723, p = 0.0006), and presence of malignant tumors (OR 6.199, 95% CI 1.593-24.129, p = 0.0085).
Conclusion: A novel mortality prediction model for LVT patients was developed, offering a valuable tool for risk assessment and treatment optimization. This model provides a valuable tool for risk assessment and treatment optimization in Asian populations, particularly in China. Further validation is required to confirm its clinical utility.
目的:左心室血栓(LVT)是一种严重的并发症,与全身栓塞和死亡风险增加有关。尽管抗凝治疗取得了进展,但全因死亡率的最佳管理策略和危险因素仍不清楚。本研究旨在建立一种预测模型来评估LVT患者的死亡风险,指导临床决策。方法与结果:本回顾性队列研究纳入2018年6月- 2023年6月在华西医院诊断的LVT患者。根据随访期间的全因死亡率将患者分为生存组和死亡组。共纳入459例患者,随机分为训练组(n = 322)和验证组(n = 137)。Logistic回归分析确定了7个独立的死亡率预测因素,并利用这些预测因素构建了基于norm图的风险预测模型。该模型具有良好的识别能力,训练集的AUC为0.846,验证集的AUC为0.791。关键的死亡率预测因素包括b型利钠肽(BNP)升高(OR 3.359, 95% CI 1.827-6.176, p = 0.0001),白蛋白水平降低(OR 0.930, 95% CI 0.882-0.981, p = 0.0077),缺乏抗血栓治疗(OR 0.468, 95% CI 0.303-0.723, p = 0.0006),以及存在恶性肿瘤(OR 6.199, 95% CI 1.593-24.129, p = 0.0085)。结论:建立了一种新的LVT患者死亡率预测模型,为LVT患者的风险评估和治疗优化提供了有价值的工具。该模型为亚洲人群,特别是中国人群的风险评估和治疗优化提供了有价值的工具。需要进一步验证以确认其临床应用。